We are live on ! Find out more
QDEL icon

QuidelOrtho

13.42 USD
+1.01
8.14%
At close Updated Oct 9, 4:00 PM EDT
Pre-market
After hours
13.25
-0.17
1.27%
1 day
8.14%
5 days
23.57%
1 month
6.17%
3 months
-23.05%
6 months
-5.16%
Year to date
-53.37%
1 year
-52.17%
5 years
-90.12%
10 years
-39.25%
 

About: QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.

Employees: 6,500

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 21.1%
Neutral 68.4%
Negative 10.5%
Neutral
PRNewsWire
3 days ago
Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Neutral
PRNewsWire
4 days ago
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho"), a leading global provider of diagnostic solutions, has appointed Sanjeev Sharma, CFA, as Vice President, Investor Relations, effective September 28, 2026. Mr. Sharma brings more than 20 years of experience across investor relations, corporate strategy and equity research at global organizations.
QuidelOrtho Appoints Sanjeev Sharma as Vice President of Investor Relations
Neutral
PRNewsWire
17 days ago
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
SAN DIEGO, Sept. 24, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader in in vitro diagnostics, is proud to share episode 61 of its Science Bytes podcast, highlighting key insights about lowering sepsis rates in the emergency room.
Early Intervention Aids Emergency Medicine Teams in Identifying and Personalizing Sepsis Treatment
Neutral
PRNewsWire
1 month ago
Faster Answers, Better Decisions: ADLM 2026 Highlights
SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode 60 of its Science Bytes podcast, featuring highlights from the 2026 Association for Diagnostics and Laboratory Medicine (ADLM) Annual Conference. Hosted by Stephanie Kleewein, the special episode showcases three presentations addressing some of healthcare's most pressing challenges: delivering faster molecular diagnostic results, improving antibiotic stewardship and accelerating cardiovascular assessment.
Faster Answers, Better Decisions: ADLM 2026 Highlights
Negative
Zacks Investment Research
1 month ago
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
Neutral
Zacks Investment Research
1 month ago
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
Positive
Zacks Investment Research
1 month ago
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
Positive
Zacks Investment Research
2 months ago
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
Neutral
Seeking Alpha
2 months ago
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
QuidelOrtho Corporation (QDEL) Q2 2026 Earnings Call Transcript
Negative
MarketBeat
2 months ago
QuidelOrtho Q2 Earnings Call Highlights
QuidelOrtho NASDAQ: QDEL reported second-quarter revenue growth despite continued pressure from China and a softer respiratory testing environment, while lowering its full-year outlook and withdrawing free cash flow guidance.
QuidelOrtho Q2 Earnings Call Highlights
Price charts implemented using Lightweight Charts™